NERX Neorx (MM)

NeoRx to Present at Invest Northwest Conference SEATTLE, April 20 /PRNewswire-FirstCall/ -- NeoRx Corporation (NASDAQ:NERX) today announced that Chairman and Chief Executive Officer Jerry McMahon, Ph.D. will present at the Invest Northwest 2005 CEO & Investor Conference taking place April 26-27, 2005 at the Bell Harbor International Convention Center in Seattle, Washington. McMahon will present Tuesday, April 26 at 2:40 p.m. Pacific Time. A live audio webcast will be available from the NeoRx Web site http://www.neorx.com/ under the "Investor Information" section. A replay of the presentation will be available for 10 days. About NeoRx NeoRx is a cancer therapeutics development company. The Company's product pipeline includes STR, a radiotherapeutic targeting bone, currently in a pivotal Phase III clinical trial for patients with multiple myeloma, and NX 473, a next-generation platinum therapy that the Company plans to evaluate in the treatment of patients with advanced lung and colorectal cancers. For more information, visit http://www.neorx.com/. This release contains forward-looking statements relating to the development of the Company's products and future operating results that are subject to certain risks and uncertainties that could cause actual results to differ materially from those projected. The words "believe," "expect," "intend", "anticipate," variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could affect the Company's actual results include the availability of financing sources for the development of NeoRx's product candidates, the progress and costs of clinical trials and the timing of regulatory approvals, the ability to successfully develop and commercialize products and the other risks and uncertainties described in NeoRx's current and periodic reports filed with the Securities and Exchange Commission, including NeoRx's Annual Report on Form 10-K for the year ended December 31, 2004. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to update any forward-looking statement to reflect new information, events or circumstances after the date of this release or to reflect the occurrence of unanticipated events. NOTE: NeoRx and STR are trademarks or registered trademarks of NeoRx Corporation in the United States and/or foreign countries. DATASOURCE: NeoRx Corporation CONTACT: Julie Rathbun of NeoRx Corporation, +1-206-286-2517, or Web site: http://www.neorx.com/

Copyright